Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin with IV Avastin [bevacizumab] Therapy in Treatment of Women with Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin.

Trial Profile

Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin with IV Avastin [bevacizumab] Therapy in Treatment of Women with Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Sep 2018 Planned End Date changed from 1 Feb 2019 to 1 Aug 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 25 Aug 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top